Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy (CIPN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a prevalent adverse effect triggered by antineoplastic medications, with its occurrence ranging from 19% to over 85%. It primarily manifests as sensory nerve damage, accompanied by varying degrees and durations of motor and autonomic alterations. Given its high occurrence among cancer patients, CIPN poses a significant challenge for patients, survivors, and their healthcare providers. This is primarily due to the absence of a single effective method to prevent CIPN. Central sensitization is pivotal in neuropathic pain, especially from nerve damage. The harm to peripheral nerves, particularly C-fibers, results in spontaneous activity that disrupts secondary neurons in the spinal dorsal horn, leading to heightened excitability due to various molecular changes. Clinically, CIPN manifests as sensory, motor, and autonomic deficits of varying severity. Sensory symptoms usually initiate the condition, typically affecting the hands and feet and resembling a classic “glove and stocking” neuropathy, with the most distal parts of the limbs exhibiting the most pronounced deficits. These symptoms encompass numbness, tingling, altered touch sensation, impaired vibration perception, paresthesias, and discomfort triggered by contact with warm or cold surfaces. Several predisposing risk factors for CIPN have been identified, including patient age (higher risk in older individuals), pre-existing neuropathy before chemotherapy (e.g., diabetic neuropathy), a history of smoking, impaired kidney function with reduced creatinine clearance, exposure to other neurotoxic chemotherapy agents, the presence of paraneoplastic antibodies, and direct neuropathy associated with the cancer itself.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034